BTIG Reiterates Buy Rating on ABIVAX Socie9te9 Anonyme

On June 30, 2026, BTIG reiterated its Buy rating on ABIVAX Socie9te9 Anonyme (NASDAQ:ABVX), setting a price target of $175. This comes as ABIVAX's stock traded at around $93.36 on Tuesday.

Other Institutional Activity in ABIVAX Socie9te9 Anonyme

Several institutional investors have recently adjusted their holdings in ABIVAX. TCG Crossover Management, LLC reduced its position by 630,511 shares, now holding 6,481,085 shares valued at about $721.7 million, an 8.9% decrease. UBS Group AG, on the other hand, increased its stake by 123,500 shares to 4,547,406 shares, worth approximately $506.4 million, reflecting a 2.8% increase. Darwin Global Management, Ltd. also added to its holdings, purchasing 290,156 shares and bringing its total to 3,468,657 shares valued at $352.1 million, a 9.1% increase. Meanwhile, Morgan Stanley significantly cut its stake by 1,447,036 shares, leaving it with 1,704,958 shares valued at $189.8 million, a 45.9% decrease.

ABIVAX Société Anonyme Stock Up 18.6%

Shares of ABIVAX Socie9te9 Anonyme (NASDAQ:ABVX) traded near $93.36 on Tuesday. The company has a market capitalization of approximately $7.78 billion. ABIVAX is not currently profitable, reflected in its negative forward P/E ratio. The stock's beta is -0.2, indicating lower volatility compared to the market. Over the past 52 weeks, the stock has ranged from $7.41 to $148.83. It has a 50-day moving average of $111.58 and a 200-day moving average of $111.21. ABIVAX maintains a strong liquidity position with a current ratio of 8.25 and a quick ratio of 8.07, alongside a debt-to-equity ratio of 7.96.

Recent Earnings

ABIVAX reported revenue of $4.92 million, showing a growth of 35.2%. However, the company posted a negative return on equity of -157.1%, and its net margin was zero. The next earnings report is expected on September 21, 2026.

Insider Buying and Selling at ABIVAX Société Anonyme

Insiders have been active in selling ABIVAX shares. Sofinnova Crossover sold 1,000,000 shares at an average price of $133.70 on January 8, 2026. Earlier, on October 28, 2025, Sofinnova Crossover SLP sold 1,200,000 shares at $92.75.

Analysts Set New Price Targets

On June 30, 2026, BTIG maintained its Buy rating on ABIVAX Socie9te9 Anonyme with a price target of $175. Earlier in June, Truist Securities and Morgan Stanley also maintained Buy ratings, with targets of $135 and $132, respectively. Jefferies downgraded the stock to Hold with a $90 target. The consensus among analysts is a Buy, with a mean target price of $150.73 based on 11 opinions.

About ABIVAX Socie9te9 Anonyme

ABIVAX Socie9te9 Anonyme is a biotechnology company based in Paris, France. It focuses on developing therapies that use the body's natural mechanisms to regulate the immune response, particularly for chronic inflammatory diseases. Its primary drug candidate, obefazimod, is in Phase 3 trials for ulcerative colitis and Phase 2b trials for Crohn's disease. The company was founded in 2013 and is led by CEO Marc de Garidel, employing around 80 people.

Bottom Line

BTIG's reiterated Buy rating with a $175 target suggests confidence in ABIVAX's future potential. The company's recent stock performance and institutional activity indicate both challenges and opportunities. Investors will be keenly watching the upcoming earnings report in September for further insights.